Nε-(1-Carboxymethyl)-L-lysine-d3
(Synonyms: CML-d3) 目录号 : GC47809
A neuropeptide with diverse biological activities
Cas No.:2699607-49-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Nε-(1-Carboxymethyl)-L-lysine-d3 (CML-d3) is intended for use as an internal standard for the quantification of CML by GC- or LC-MS. CML is an advanced glycation end product (AGE), produced by the oxidative modification of glycated proteins during oxidative stress.1,2,3 Levels of CML increase with aging and during diabetes, cancer, vascular disease, and other pathologies marked by oxidative stress.1,4,5 CML activates the membrane-bound receptor for AGEs (RAGE), triggering signaling through MAPKs and NF-κB, whereas truncation of RAGE produces a soluble protein that binds CML and reduces signaling.6,7
1.Requena, J.R., Ahemd, M.U., Fountain, C.W., et al.Carboxymethylethanolamine, a biomarker of phospholipid modification during the maillard reaction in vivoThe Journal of Biological Chemisty272(28)17473-17479(1997) 2.Ahmed, M.U., Brinkmann, F.E., Degenhardt, T.P., et al.Nε-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteinsBiochem. J.324(Pt 2)565-570(1997) 3.Schleicher, E.D., Wagner, E., and Nerlich, A.G.Increased accumulation of the glycoxidation product Nε-(carboxymethyl)lysine in human tissues in diabetes and agingJournal of Clinical Investigation99(3)457-468(1997) 4.Campbell, D.J., Somaratne, J.B., Jenkins, A.J., et al.Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery diseaseCardiovascular Diabetology101-14(2011) 5.Brouwers, O., de Vos-Houben, J.M.J., Niessen, P.M.G., et al.Mild oxidative damage in the diabetic rat heart is attenuated by glyoxalase-1 overexpressionInternational Journal of Molecular Sciences14(8)15724-15739(2013) 6.Schmidt, A.M., Yan, S.D., Yan, S.F., et al.The biology of the receptor for advanced glycation end products and its ligandsBiochimica et Biophysica Acta1498(2-3)99-111(2000) 7.Moy, K.A., Jiao, L., Freedman, N.D., et al.Soluble receptor for advanced glycation end products and risk of liver cancerHepatology57(6)2338-2345(2013)
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.8263 mL | 24.1313 mL | 48.2625 mL |
| 5 mM | 0.9653 mL | 4.8263 mL | 9.6525 mL |
| 10 mM | 0.4826 mL | 2.4131 mL | 4.8263 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。